SARS-CoV-2 (Covid-19) research.

Current activities

With great commitment, the researchers of the network are currently engaged in various research groups and projects to research and fight the virus, which paralyzes our world economically, socially and culturally due to its pandemic proportions. Below, you will find a list of the current activities of the members of bayresq.net, regarding current activities:

  • Effect of Na+ on SARS-CoV2 replication.
    (Prof. Jonathan Jantsch, PD Dr. Katja Dettmer, Prof. Rainer Spang, Prof. Barbara Schmidt, Universität Regensburg)
  • Task Force Leader “Research Network COVID-19”, coordination of sample collection at the Regensburg site, biobanking includes serum and cellular components of patients (BMBF).
    ( Prof. André Gessner, Universität Regensburg)
  • Recovery of antibodies from recovered COVID-19 patients.
    (Prof. André Gessner, Universität Regensburg)
  • Relating the impact of SARS-CoV2 on the microbiome and its role in disease development.
    (Prof. André Gessner, Universität Regensburg)
  • LBP proteins as novel immunomodulators in SARS-CoV2.
    (Prof. André Gessner, Universität Regensburg)
  • Detectability of tissue healing by regulatory T cells.
    (Prof. Markus Feuerer und Prof. Uwe Ritter, Universität Regensburg)
  • RNA vaccine development.
    (Prof. Jochen Vogel, Universität Würzburg)
  • Analysis of a dataset of over 1000 Covid 19 patients from the Netherlands and Germany with regard to the association of disease progression and different antihypertensive drugs.
    (Prof. Michael Floßdorf, Prof. Heribert Schunkert und Prof. Yigal Pinto)
  • Single cell gene expression to identify prognostic markers for disease progression.
    (Prof. Michael Floßdorf und Prof. Oliver Söhnlein)
  • Predicting county-level time trends in Bavaria using vector autoregression.
    (Prof. Christian L. Müller, LMU München)
  • Determination of protective immune responses in patients/employees who have undergone COVID-19 and validation of new specific test systems developed for this purpose.
    (Prof. Markus Gerhard, Institut für Medizinische Mikrobiologie, Immunologie und Hygiene; Mikrogen GmbH; Universität Barcelona; ISGlobal, Barcelona)
  • Participation in CoMRI cohort study and the SeCoMRI staff study.
    (Prof. Markus Gerhard, Institut für Medizinische Mikrobiologie, Immunologie und Hygiene; Mikrogen GmbH; Universität Barcelona; ISGlobal, Barcelona)
  • New method based on CRISPER/Cas9 nuclease of Campylobacter jejuni, approach for diagnostic application – especially suitable for the detection of RNA viruses such as SARS-CoV2. The method is established on this example.
    (Prof. Cynthia Sharma und Prof. Chase Beisel, Universität Würzburg)